Related Experiment Video
Updated: Jun 28, 2025
08:34
Technique of Minimally Invasive Transverse Aortic Constriction in Mice for Induction of Left Ventricular Hypertrophy
Published on: September 25, 2017
24.4K
Prevention and treatment of hypertensive left ventricular hypertrophy
Manvita Tatavarthy1, John Stathopoulos1, Ahmet Afşin Oktay2
1Department of Medicine.
Current Opinion in Cardiology
|April 11, 2024
Summary
Left ventricular hypertrophy (LVH) is a common complication of hypertension. Early detection and management, including lifestyle changes and blood pressure control, are key to preventing and reversing LVH for better cardiovascular health.
Area of Science:
- Cardiology
- Hypertension Research
- Medical Imaging
Background:
- Left ventricular hypertrophy (LVH) is a significant adaptation to uncontrolled hypertension and a predictor of cardiovascular disease.
- It often develops silently in patients with hypertension.
Purpose of the Study:
- To review current strategies for screening, diagnosing, preventing, and treating LVH in hypertensive individuals.
- To highlight the role of emerging technologies like machine learning in LVH detection.
Main Methods:
- Review of current screening and diagnostic tools for LVH, including ECG and 2D echocardiography.
- Exploration of the potential of machine learning to enhance LVH detection sensitivity.
- Discussion of preventive and therapeutic interventions for LV remodeling.
Main Results:
- ECG and 2D echocardiography are primary diagnostic tools for LVH.
- Machine learning shows promise for improving LVH detection accuracy.
- Lifestyle modifications, blood pressure control, and comorbidity management are vital for preventing and reversing LVH.
Conclusions:
- LVH is a frequent, often asymptomatic, consequence of hypertension.
- Preventing and reversing LVH is critical for reducing cardiovascular risk in hypertensive patients.
More Related Videos
Related Concept Videos
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
156
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
156
01:22Heart Failure Drugs: Diuretics
370
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
370
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
160
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
160
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:18Hypertension and Regulation of Blood Pressure
2.1K
Hypertension, the most common cardiovascular disease, is diagnosed through repeated measurements of elevated blood pressure. Its risks, including damage to the kidney, heart, and brain, are directly proportional to blood pressure levels. Starting from 115/75 mm Hg, the risk of cardiovascular disease doubles with each increment of 20/10 mm Hg. The diagnosis relies on blood pressure measurements, not on patient symptoms, as hypertension is often asymptomatic until end-organ damage is imminent or...
2.1K